El péptido natriurético endotelial de tipo C mantiene la homeostasis vascular

Fernández-Llama, P.
Hipertens. riesgo vasc ; 32(3): 127-128, jun.-sept. 2015.
Artículo en Español | IBECS (España) | ID: ibc-140207

Documentos relacionados

  1. Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study.
  2. A long-acting C-natriuretic peptide for achondroplasia.
  3. Pharmacological and Genetic Disruption of C-Type Natriuretic Peptide (<i>nppcl</i>) Expression in Zebrafish (<i>Danio rerio</i>) Causes Stunted Growth during Development.
  4. "Meiosis arrester" C-natriuretic peptide directly stimulates oocyte mtDNA accumulation and is implicated in aging-associated oocyte mtDNA loss.
  5. Efficacy of vosoritide in the treatment of achondroplasia.
  6. TransCon CNP, a Sustained-Release C-Type Natriuretic Peptide Prodrug, a Potentially Safe and Efficacious New Therapeutic Modality for the Treatment of Comorbidities Associated with Fibroblast Growth Factor Receptor 3-Related Skeletal Dysplasias.
  7. Advantages and Disadvantages of Different Treatment Methods in Achondroplasia: A Review.
  8. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial.
  9. Vosoritide Therapy in Children with Achondroplasia: Early Experience and Practical Considerations for Clinical Practice.
  10. C-type natriuretic peptide induces inotropic and lusitropic effects in human 3D-engineered cardiac tissue: Implications for the regulation of cardiac function in humans.